Complications of human immunodeficiency virus therapy

Pediatric Infectious Disease Journal

Volumn 23, Issue 9, 2004, Pages 873-874

  Hayes, Ericka V ^a   McGann, Kathleen A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Highly active antiretroviral therapy; Human immunodeficiency virus

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANEMIA; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LETHARGY; LIPODYSTROPHY; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; NEPHROLITHIASIS; NEUTROPENIA; PANCREATITIS; PARESTHESIA; PERSONALITY DISORDER; PRIORITY JOURNAL; RASH; SHORT SURVEY; SIDE EFFECT; SLEEP DISORDER; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FATTY LIVER; FEMALE; FOLLOW UP; HOSPITALIZATION; HYPERLIPIDEMIA; INCIDENCE; LIVER DISEASE; MALE; METHODOLOGY; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; INSULIN RESISTANCE; LIVER DISEASES; MALE; OSTEOPOROSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 6344254670     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000138748.94177.02     Document Type: Short Survey

References (17)

1. CDC. HIV/AIDS Surveillance Report 2002. 2003:1-48.
2. McKinney RE. In: SS Long et al, eds. Principles and Practice of Pediatric Infectious Diseases, New York, NY: Churchill Livingstone; 2002:679-684.
3. Lewis W, et al. Mitochondrial toxicity of NRTI antiviral drugs:. . .. Nat Rev Drug Discov 2003;2:812-822.
4. Powderly WG. Limitations of current HIV therapies:. . .. J Acquir Immune Defic Syndr 2003;33(suppl 1):S7-S12.
5. Lesho EP, et al. Managing issues related to antiretroviral therapy. Am Fam Physician 2003;68:675-686.
6. Leonard EG, et al. Metabolic complications of antiretroviral. . .. Pediatr Infect Dis J 2003; 22:77-84.
7. Bockhorst JL, et al. Evidence of HIV-associated lipodystrophy syndrome. . .. Pediatr Infect Dis J 2003;22:463-465.
8. Amaya RA, et al. Lipodystrophy syndrome. . .. Pediatr Infect Dis J 2002;21:405-410.
9. Ogedegbe AO, et al. Antiretroviral-associated liver injury. Clin Liver Dis 2003;7:475-499.
10. Dieterich DT, et al. Drug-induced liver injury. . .. Clin Infect Dis 2004;38(suppl 2): S80-S89.
11. Desai N, et al. Lactate levels in children. . .. AIDS 2003;17:1565-1568.
12. Rey C, et al. Fatal lactic acidosis. . .. Pediatr Crit Care Med 2003;4:485-487.
13. Rosso R, et al. Fatal lactic acidosis. . .. Pediatr Infect Dis J 2003;22:668-670.
14. Barret B, et al. Persistent mitochondrial dysfunction. . .. AIDS 2003;17:1769-1785.
15. Tebas P, et al. Accelerated bone mineral loss. . .. AIDS 2000;14:F63-F67.
16. Mora S, et al. Longitudinal changes of bone mineral density and metabolism. . .. J Clin Endocrinol Metab 2004;89:24-28.
17. Mondy K, et al. Longitudinal evolution of bone mineral density and bone markers. . .. Clin Infect Dis 2003;36:482-490.